Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High infusion rate safety study of NewGam in primary immunodeficiency (extension of NGAM 01)
2011-005015-82Phase 3
- Sponsor
- Octapharma
- Start
- Jan 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of subcuvia in Immunogenetic disorder, X-linked agammaglobulinemia (XLA), sponsored by Octapharma.
02
Drugs
subcuvia
03
Conditions
Immunogenetic disorderX-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on 2011-005015-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005015-82.